INVESTOR

Novavax NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial

Tuesday, March 24, 2020
8:30am EDT
Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at [email protected]

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.

Graph icon